Acute Impairment of Mitochondrial Trafficking by β-Amyloid Peptides in Hippocampal Neurons

Defects in axonal transport are often associated with a wide variety of neurological diseases including Alzheimer's disease (AD). β-Amyloid (Aβ) is a major component of neuritic plaques associated with pathological conditions of AD brains. Here, we report that a brief exposure of cultured hippocampal neurons to Aβ molecules resulted in rapid and severe impairment of mitochondrial transport without inducing apparent cell death and significant morphological changes. Such acute inhibition of mitochondrial transport was not associated with a disruption of mitochondria potential nor involved aberrant cytoskeletal changes. Aβ also did not elicit significant Ca2+ signaling to affect mitochondrial trafficking. However, stimulation of protein kinase A (PKA) by forskolin, cAMP analogs, or neuropeptides effectively alleviated the impairment. We also show that Aβ inhibited mitochondrial transport by acting through glycogen synthase kinase 3β (GSK3β). Given that mitochondria are crucial organelles for many cellular functions and survival, our findings thus identify an important acute action of Aβ molecules on nerve cells that could potentially contribute to various abnormalities of neuronal functions under AD conditions. Manipulation of GSK3β and PKA activities may represent a key approach for preventing and alleviating Aβ cytotoxicity and AD pathological conditions.

[1]  F. Saatcioglu,et al.  Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation. , 2008, Neoplasia.

[2]  M. Tabaton,et al.  The various aggregation states of beta-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. , 2006, Free radical biology & medicine.

[3]  I. Reynolds,et al.  Mitochondrial Trafficking to Synapses in Cultured Primary Cortical Neurons , 2006, The Journal of Neuroscience.

[4]  G. Perry,et al.  Alzheimer's disease: an intracellular movement disorder? , 2005, Trends in molecular medicine.

[5]  E. Masliah,et al.  Axonopathy and Transport Deficits Early in the Pathogenesis of Alzheimer's Disease , 2005, Science.

[6]  Yasunori Hayashi,et al.  The Importance of Dendritic Mitochondria in the Morphogenesis and Plasticity of Spines and Synapses , 2004, Cell.

[7]  M. Duchen,et al.  Calcium signals induced by amyloid beta peptide and their consequences in neurons and astrocytes in culture. , 2004, Biochimica et biophysica acta.

[8]  C. Finch,et al.  Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers , 2004, The Journal of Neuroscience.

[9]  B. Eickholt,et al.  A molecular cell biology of lithium. , 2004, Biochemical Society transactions.

[10]  R. Anwyl,et al.  Mechanisms of the inhibitory effects of amyloid β-protein on synaptic plasticity , 2004, Experimental Gerontology.

[11]  M. Mattson Pathways towards and away from Alzheimer's disease , 2004, Nature.

[12]  S. Lipton,et al.  Molecular pathways to neurodegeneration , 2004, Nature Medicine.

[13]  C. Ross,et al.  Protein aggregation and neurodegenerative disease , 2004, Nature Medicine.

[14]  Michael P. Sheetz,et al.  Axonal mitochondrial transport and potential are correlated , 2004, Journal of Cell Science.

[15]  M. Duchen,et al.  β-Amyloid Peptides Induce Mitochondrial Dysfunction and Oxidative Stress in Astrocytes and Death of Neurons through Activation of NADPH Oxidase , 2004, The Journal of Neuroscience.

[16]  D. Selkoe Folding proteins in fatal ways , 2003, Nature.

[17]  B. Winblad,et al.  Apolipoprotein E and β‐amyloid (1–42) regulation of glycogen synthase kinase‐3β , 2003 .

[18]  Anne Eckert,et al.  Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. , 2003, Biochemical pharmacology.

[19]  T. Kawakami,et al.  Glutamate and Amyloid β-Protein Rapidly Inhibit Fast Axonal Transport in Cultured Rat Hippocampal Neurons by Different Mechanisms , 2003, The Journal of Neuroscience.

[20]  Mark P Mattson,et al.  Neuronal and glial calcium signaling in Alzheimer's disease. , 2003, Cell calcium.

[21]  M. Duchen,et al.  Changes in Intracellular Calcium and Glutathione in Astrocytes as the Primary Mechanism of Amyloid Neurotoxicity , 2003, The Journal of Neuroscience.

[22]  J. Waschek Multiple Actions of Pituitary Adenylyl Cyclase Activating Peptide in Nervous System Development and Regeneration , 2002, Developmental Neuroscience.

[23]  Hai Lin,et al.  Imaging real-time aggregation of amyloid beta protein (1–42) by atomic force microscopy , 2002, Peptides.

[24]  H. Orr,et al.  The GSK3β signaling cascade and neurodegenerative disease , 2002, Current Opinion in Neurobiology.

[25]  G. Perry,et al.  Amyloid-β, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs? , 2002, Neurochemistry International.

[26]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[27]  H. Eldar-Finkelman Glycogen synthase kinase 3: an emerging therapeutic target. , 2002, Trends in molecular medicine.

[28]  Nancy Ratner,et al.  Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin‐based motility , 2002, The EMBO journal.

[29]  Brett Chromy,et al.  Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus , 2002, Brain Research.

[30]  R. Jope,et al.  The multifaceted roles of glycogen synthase kinase 3β in cellular signaling , 2001, Progress in Neurobiology.

[31]  L. Greene,et al.  β‐Amyloid‐induced neuronal apoptosis requires c‐Jun N‐terminal kinase activation , 2001, Journal of neurochemistry.

[32]  D. Choi,et al.  Assessment of Cell Viability in Primary Neuronal Cultures , 2000, Current protocols in neuroscience.

[33]  J W Yates,et al.  Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. , 2000, Chemistry & biology.

[34]  R. Lal,et al.  Fresh and globular amyloid β protein (1–42) induces rapid cellular degeneration: evidence for AβP channel‐mediated cellular toxicity , 2000 .

[35]  H. Manji,et al.  The Mood‐Stabilizing Agent Valproate Inhibits the Activity of Glycogen Synthase Kinase‐3 , 2000, Journal of neurochemistry.

[36]  M. Kiebler,et al.  Fast, convenient, and effective method to transiently transfect primary hippocampal neurons , 1999, Journal of neuroscience research.

[37]  A. Bacci,et al.  Synaptic and intrinsic mechanisms shape synchronous oscillations in hippocampal neurons in culture , 1999, The European journal of neuroscience.

[38]  A. Takashima,et al.  Activation of tau protein kinase I/glycogen synthase kinase-3β by amyloid β peptide (25–35) enhances phosphorylation of tau in hippocampal neurons , 1998, Neuroscience Research.

[39]  J. Jordán,et al.  Role of Calpain‐ and Interleukin‐1β Converting Enzyme‐Like Proteases in the β‐Amyloid‐Induced Death of Rat Hippocampal Neurons in Culture , 1997 .

[40]  B. Seilheimer,et al.  A Biotechnological Method Provides Access to Aggregation Competent Monomeric Alzheimer's 1–42 Residue Amyloid Peptide , 1995, Bio/Technology.

[41]  C. Cotman,et al.  Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[42]  C. Cotman,et al.  Structure‐Activity Analyses of β‐Amyloid Peptides: Contributions of the β25–35 Region to Aggregation and Neurotoxicity , 1995 .

[43]  W. Maxwell Cowan,et al.  Rat hippocampal neurons in dispersed cell culture , 1977, Brain Research.

[44]  R. Anwyl,et al.  Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity. , 2004, Experimental gerontology.

[45]  C. Finch,et al.  Synaptic targeting by Alzheimer's-related amyloid beta oligomers. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[46]  B. Winblad,et al.  Apolipoprotein E and beta-amyloid (1-42) regulation of glycogen synthase kinase-3beta. , 2003, Journal of neurochemistry.

[47]  W Blaine Stine,et al.  Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. , 2002, Brain research.

[48]  H. Orr,et al.  The GSK3 beta signaling cascade and neurodegenerative disease. , 2002, Current opinion in neurobiology.

[49]  F. Leuven,et al.  Axonal transport, tau protein, and neurodegeneration in Alzheimer’s disease , 2002, NeuroMolecular Medicine.

[50]  H. Lin,et al.  Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[51]  A. Takashima,et al.  Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. , 1998, Neuroscience research.

[52]  R. Miller,et al.  Role of calpain- and interleukin-1 beta converting enzyme-like proteases in the beta-amyloid-induced death of rat hippocampal neurons in culture. , 1997, Journal of neurochemistry.

[53]  L. B. Chen,et al.  Mitochondrial membrane potential monitored by JC-1 dye. , 1995, Methods in enzymology.

[54]  C. Cotman,et al.  Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. , 1995, Journal of neurochemistry.